Oxford Nanopore Technologies’ Post

Advancing Biopharma quality control: Oxford Nanopore Technologies at NCM Boston 2024 As the biopharma industry continues to rapidly evolve with cutting-edge therapies and evolving regulatory expectations, the demand for innovative solutions has never been greater. At today’s Biopharma Day at NCM Boston 2024, Oxford Nanopore’s customers highlighted how the platform is shaping the future of a rapidly evolving sector. https://lnkd.in/g6xub78g

Is investing into Advanced Therapeutic Modalities the right move for Biopharma industry? Find out in this HBR article. https://lnkd.in/dbHQnTee

If you missed the live session, the recorded webinar is now available! Key takeaways include unveiling how the XCell® ATF System achieves 2-10x higher titers for various biologics compared to traditional fed-batch processes. Dive into how top biopharma companies leverage ATF and TFDF technology to speed up market entry and increase facility capacity. Gain insights on linearly scaling from process development to clinical and commercial scale manufacturing.

Last 2 days to register! Join us for an informative presentation by Frank Lau, MD, FACS on Keliomics' #breakthrough technology for #preclinical efficacy testing and #biomarker/companion diagnostic development. The ex vivo technology was developed in Dr. Lau’s tissue-engineering lab and is poised to revolutionize cancer treatment by keeping human tissues and #tumors alive outside the human body for 8 weeks! Keliomics platform for organ-scale biology preserves the full composition, structure, and function of primary human tissues, and may lead to transformative changes in #preclinical #efficacy testing of novel #therapeutics in #breastcancer, #coloncancer, #melanoma, and #peritoneal #metastases of #solidtumors. The platform is being piloted in labs at Duke, UT Southwestern, UC Berkeley, Tulane, LSU, and Legacy Health. Keliomics has raised $2.5 million of a $7 million Seed round. Frank will highlight the competitive advantages that #biopharmaceutical companies can gain by incorporating Keliomics’ ex vivo organs and tumors into their development plans. The event is generously sponsored by Stat4ward. OccamPoint's mission is to amplify professional awareness about methodologies and technological advancements that transformatively increase #efficiency of #productdevelopment in #healthcare, #lifesciences and #medicinal products. Each webinar is delivered to a curated audience of experts in product development and investment communities, with a live Q&A and opportunity to meet the speakers and sponsors. If you are interested in presenting or sponsoring an OccamPoint Webinar, visit https://lnkd.in/eTZ3uNc6 to submit an inquiry. A Breakthrough Organ-Scale Biology Platform for Drug Development When: Wednesday March 27th 1:00 - 2:00 PM PST / 4:00 - 05:00 PM EST Click below to learn more and to register: https://lnkd.in/grus-Aqj

How might traditional #ELISA methods hold back preclinical PK studies? Learn how advanced microfluidic technology can streamline immunoassay workflows, reduce sample volumes, and save precious lab time. 👉 Dive into our latest expert article to learn more! #Biotech #Bioanalysis #pharmacokinetics https://lnkd.in/gRcnzXwh

Did you miss our latest webinar from Catalent Pharma Solutions? Our speakers have put together an exclusive follow-up Q&A to answer all our audience questions. Find out what your peers are asking >>> https://bit.ly/3wjpIZf

Mirus sold again?? Interesting to see Gamma Bio sell off Mirus Bio asset to Merck KGaA. This is a company with transfection reagents that has been around the market for a long time. Originally bought by Roche in ~2008, parts of it were sold to Arrowhead three years later. The IP has been split up a few times. Most recently, it was acquired by Gamma Bio, a KKR-backed rollup that set out in 2019. Transfection reagents, particularly those of the GMP variety are of increasing importance for producing viruses (of multiple flavors) and other cell-based products. This, traditionally, was a space PolyPlus owned as one of the only vendors offering a GMP transfection reagent. PolyPlus was also recently transacted on with Sartorius acquiring them for $2.6B! A bit surprising to see Gamma selling off just Mirus at this point in the rollup, but perhaps the price was right given other happenings in the market. We expect to see no slow down in PE-backed life science roll ups as the market continues to heat up. Key will be differentiated, high-quality assets that solve real pain points in bioprocessing / manufacturing. Want to discuss this or other market developments? Reach out! #pharma #investing #drugdevelopment https://lnkd.in/g3kgn9sJ

The complexities inherent in today’s biopharmaceutical development paradigm have necessitated novel approaches for early phase workflows that can accelerate timelines and reduce cost and risk. For both process and analytical development (PD and AD) in the advanced therapy space, this drive toward more automated, closed processing has led to unprecedented innovation aimed at standardizing these workflows to the same degree as more incumbent therapeutic modalities. Yet this pursuit of fully automated, completely closed PD and AD can serve to create new challenges for a workflow. Comprehensive Cell Solutions (CCS) shares how pursuing targeted #automation and modularity for a program can help developers eliminate common workflow bottlenecks, improve manufacturing reproducibility, and establish a highly flexible and controlled development paradigm that can adapt to technical and business considerations.

🌍🌟Exciting News from ACCESS CHINA Partnering Forum @ JPM 2024. We are thrilled to announce that 40+ Innovative biotech presentations are now available online. Our presenting companies include both Chinese and international firms, spanning diverse fields such as oncology, immunology, CNS, metabolism, and more, specializing in areas such as antibody, small molecules, cell therapy, medical technology, and digital health. To access these presentations, please first register here: https://lnkd.in/dTexv7d Here's a sneak peek at some of the presenting companies: 💡Minomic International Next-gen blood test | Prostate cancer | Registered 💡Biostar Pharma Genetically engineered best-in-class epothilone analog to overcome drug resistance | mBC, BC neoadjuvant, NSCLC, gastric cancer, esophagus cancer, et al | Registered 💡 Legacy Healthcare The Only Treatment Worldwide for Most Types of Alopecia | Alopecia Areata | Pre-registration (NDA submitted) 💡 Candel Therapeutics HSV-1 based Oncolytic Viral Immunotherapies| Recurrent high-grade glioma (glioblastoma), Non-small cell lung cancer, Borderline resectable pancreatic cancer, Early, localized prostate cancer | Ph3 ongoing 💡 Daewoong Pharma Best-in-class SGLT2 inhibitor in Ph3 (Enavogliflozin) | Type 2 Diabetes Mellitus, Obesity, Heart failure, Proteinuria, etc. | Ph3 💡 Lytix BioPharma First-in-class Oncolytic Molecule Therapy with Positive Phase II Interim Data | Melanoma; metastatic and refractory | Ph2 completed 💡 TaiRx First-in-class Anti-tumor Oral TRAP1 Inhibitor | Liver cancer and neuroendocrine tumors | Ph2 ongoing 💡 Qurebio CLDN18.2/ PD-L1 bi-specific antibody, with high ORR rate and the DCR rate | Gastric cancer, gastroesophageal junction cancer, biliary tract cancer | Ph2 ongoing 💡 Xuanzhu Biopharma Several First-in-class and Best-in-class Oncology Assets | Solid tumors with low or moderate Her2 expression, or benchmark drug resistance | Ph1 ongoing 💡 Shengke Pharma Global First Ph1 Stage PIM/CDK dual-targeting inhibitor | AML/NHL/solid tumors | Ph1 ongoing 💡 Latticon Antibody Therapeutics, Inc. Bispecific antibody fusion protein that combines the functionality of two different antibodies | Solid tumors | Ph1 ongoing 💡 Bilayer Therapeutics First-in-class therapy for Chronic Constipation | Constipation | IND 💡 Likang Life Sciences Neoantigen-based mRNA-DC Vaccine | Solid tumors, including Liver cancer, Melanoma, Pancreatic cancer, Lung cancer, etc | Pre-clinical 💡 XtalPi Best-in-class NLRP3 inhibitor with excellent DMPK/PD properties | CAPS, osteoarthritis, RA, IBD, etc. | Pre-clinical Join us at ACCESS CHINA Partnering Forum @ JPM 2024. Dive into the future of biotech with us! 🌐🚀 For more information about ACCESS CHINA @ JPM 2024, please visit Biotochina.org. If you have any questions, please contact: Wendi Xiang, VP [email protected]

It is so exciting to see all the amazing places BioSpherix, LLC Xvivo systems are being used and what they are being used for!! How can BioSpherix help you grow high quality cells??